Developing a stability indicating method for the analysis of a complex combination drug product

Swedish speciality pharmaceutical company, Lobsor Pharmaceutical AB, recently gained approval for its advanced Parkinson’s disease (PD) treatment, Lecigon® intestinal gel. A combination drug product containing three active pharmaceutical ingredients (APIs) in a viscous gel, the treatment is continually administered directly to the small intestine via a small portable pump enabling a dosage within the narrowing therapeutic window in advanced PD.

Recipharm’s approach to provide customer tailored development and support, adapted to the specific demands of this complex drug product, were key factors to the successful outcome of this project.

Register below to download the full case study.